Literature DB >> 33258687

Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Ethan Basch1,2, Claus Becker3, Lauren J Rogak2, Deborah Schrag4, Bryce B Reeve5, Patricia Spears1, Mary Lou Smith6, Mrinal M Gounder2, Michelle R Mahoney7, Gary K Schwartz8, Antonia V Bennett1, Tito R Mendoza9, Charles S Cleeland9, Jeff A Sloan7, Deborah Watkins Bruner10, Gisela Schwab11, Thomas M Atkinson2, Gita Thanarajasingam12, Monica M Bertagnolli13, Amylou C Dueck14.   

Abstract

BACKGROUND: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library designed for eliciting patient-reported adverse events in oncology. For each adverse event, up to three individual items are scored for frequency, severity, and interference with daily activities. To align the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events with other standardized tools for adverse event assessment including the Common Terminology Criteria for Adverse Events, an algorithm for mapping individual items for any given adverse event to a single composite numerical grade was developed and tested.
METHODS: A five-step process was used: (1) All 179 possible Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events score combinations were presented to 20 clinical investigators to subjectively map combinations to single numerical grades ranging from 0 to 3. (2) Combinations with <75% agreement were presented to investigator committees at a National Clinical Trials Network cooperative group meeting to gain majority consensus via anonymous voting. (3) The resulting algorithm was refined via graphical and tabular approaches to assure directional consistency. (4) Validity, reliability, and sensitivity were assessed in a national study dataset. (5) Accuracy for delineating adverse events between study arms was measured in two Phase III clinical trials (NCT02066181 and NCT01522443).
RESULTS: In Step 1, 12/179 score combinations had <75% initial agreement. In Step 2, majority consensus was reached for all combinations. In Step 3, five grades were adjusted to assure directional consistency. In Steps 4 and 5, composite grades performed well and comparably to individual item scores on validity, reliability, sensitivity, and between-arm delineation.
CONCLUSION: A composite grading algorithm has been developed and yields single numerical grades for adverse events assessed via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, and can be useful in analyses and reporting.

Entities:  

Keywords:  Adverse event; Common Terminology Criteria for Adverse Events; Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; health-related quality of life; oncology; patient-reported outcome; symptom; toxicity

Mesh:

Substances:

Year:  2020        PMID: 33258687      PMCID: PMC7878323          DOI: 10.1177/1740774520975120

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  16 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  Sorafenib for Advanced and Refractory Desmoid Tumors.

Authors:  Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

3.  Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.

Authors:  Molly McFatrich; Jennifer Brondon; Nicole R Lucas; Pamela S Hinds; Scott H Maurer; Jennifer W Mack; David R Freyer; Shana S Jacobs; Justin N Baker; Catriona Mowbray; Mian Wang; Sharon M Castellino; Allison Barz Leahy; Bryce B Reeve
Journal:  Cancer       Date:  2019-09-25       Impact factor: 6.860

4.  Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.

Authors:  Janice Kim; Harpreet Singh; Kassa Ayalew; Kristina Borror; Michelle Campbell; Laura Lee Johnson; Alyson Karesh; Ni A Khin; Joanne R Less; Jerry Menikoff; Lori Minasian; Sandra A Mitchell; Elektra J Papadopoulos; Richard L Piekarz; Kevin A Prohaska; Susan Thompson; Rajeshwari Sridhara; Richard Pazdur; Paul G Kluetz
Journal:  Clin Cancer Res       Date:  2017-12-13       Impact factor: 12.531

5.  Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Authors:  Ethan M Basch; Mark Scholz; Johann S de Bono; Nicholas Vogelzang; Paul de Souza; Gavin Marx; Ulka Vaishampayan; Saby George; James K Schwarz; Emmanuel S Antonarakis; Joseph M O'Sullivan; Arash Rezazadeh Kalebasty; Kim N Chi; Robert Dreicer; Thomas E Hutson; Amylou C Dueck; Antonia V Bennett; Erica Dayan; Milan Mangeshkar; Jaymes Holland; Aaron L Weitzman; Howard I Scher
Journal:  Eur Urol       Date:  2018-12-04       Impact factor: 20.096

6.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Authors:  Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2009-11-17       Impact factor: 13.506

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

Review 8.  Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data.

Authors:  Ethan Basch; Amylou C Dueck
Journal:  Expert Opin Drug Discov       Date:  2016-06-16       Impact factor: 6.098

9.  Comparing higher order models for the EORTC QLQ-C30.

Authors:  Chad M Gundy; Peter M Fayers; Mogens Groenvold; Morten Aa Petersen; Neil W Scott; Mirjam A G Sprangers; Galina Velikova; Neil K Aaronson
Journal:  Qual Life Res       Date:  2011-12-21       Impact factor: 4.147

10.  Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Antonia V Bennett; Amylou C Dueck; Sandra A Mitchell; Tito R Mendoza; Bryce B Reeve; Thomas M Atkinson; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Jay K Harness; James D Bearden; Donna Bryant; Robert D Siegel; Deborah Schrag; Ethan Basch
Journal:  Health Qual Life Outcomes       Date:  2016-02-19       Impact factor: 3.186

View more
  21 in total

Review 1.  Conventional Laparoscopy versus Robotic-Assisted Aortic Lymph-Nodal Staging for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Mariano Catello Di Donna; Vincenzo Giallombardo; Giuseppina Lo Balbo; Giuseppe Cucinella; Giulio Sozzi; Vito Andrea Capozzi; Antonino Abbate; Antonio Simone Laganà; Simone Garzon; Vito Chiantera
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

2.  Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant.

Authors:  Surbhi Sidana; Amylou C Dueck; Gita Thanarajasingam; Joan M Griffin; Carrie Thompson; Urshila Durani; Michelle Burtis; Rahma Warsame; Jonas Paludo; Morie A Gertz; Angela Dispenzieri; Stephen M Ansell; S Vincent Rajkumar; Kathleen Yost; Nora Bennani; Yi Lin; Shaji Kumar
Journal:  Transplant Cell Ther       Date:  2022-05-09

Review 3.  Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Vishal Bhatnagar; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; Nicole Gormley; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Yok Lam Kwong; Richard F Little; Matthew J Matasar; Maria-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Abhilasha Nair; Loretta Nastoupil; Kaye Robertson; Surbhi Sidana; Karin E Smedby; Pieter Sonneveld; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2022-05       Impact factor: 30.153

4.  A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Lilja B Solnes; Michael A Gorin; Nae-Yuh Wang; Steven P Rowe
Journal:  Eur Urol       Date:  2021-04-08       Impact factor: 20.096

5.  Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.

Authors:  Tracy L Rose; Michael R Harrison; Allison M Deal; Sundhar Ramalingam; Young E Whang; Blaine Brower; Mary Dunn; Chelsea K Osterman; Hillary M Heiling; Marc A Bjurlin; Angela B Smith; Matthew E Nielsen; Hung-Jui Tan; Eric Wallen; Michael E Woods; Daniel George; Tian Zhang; Anthony Drier; William Y Kim; Matthew I Milowsky
Journal:  J Clin Oncol       Date:  2021-08-24       Impact factor: 50.717

6.  Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients.

Authors:  Daniel Boakye; Lina Jansen; Niels Halama; Jenny Chang-Claude; Michael Hoffmeister; Hermann Brenner
Journal:  Ther Adv Med Oncol       Date:  2021-04-22       Impact factor: 8.168

7.  Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data.

Authors:  Blake Langlais; Gina L Mazza; Gita Thanarajasingam; Lauren J Rogak; Brenda Ginos; Narre Heon; Howard I Scher; Gisela Schwab; Patricia A Ganz; Ethan Basch; Amylou C Dueck
Journal:  J Pain Symptom Manage       Date:  2021-08-08       Impact factor: 3.612

Review 8.  Understanding Treatment Tolerability in Older Adults With Cancer.

Authors:  Marie A Flannery; Eva Culakova; Beverly E Canin; Luke Peppone; Erika Ramsdale; Supriya G Mohile
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 44.544

9.  Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina.

Authors:  Christoph Wohlmuth; Iris Wohlmuth-Wieser; Stéphane Laframboise
Journal:  J Low Genit Tract Dis       Date:  2021-04-01       Impact factor: 3.842

Review 10.  Strategies to Mitigate Chemotherapy and Radiation Toxicities That Affect Eating.

Authors:  Peter M Anderson; Stefanie M Thomas; Shauna Sartoski; Jacob G Scott; Kaitlin Sobilo; Sara Bewley; Laura K Salvador; Maritza Salazar-Abshire
Journal:  Nutrients       Date:  2021-12-08       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.